A chasm has opened up between biomedical researchers and the patients who need their discoveries. Declan Butler asks how the ground shifted and whether the US National Institutes of Health can bridge the gap.
This is a preview of subscription content, log in via an institution to check access.
Additional information
See also pages 823 and 843, and online at http://tinyurl.com/3tt3y3 Declan Butler is a senior reporter at Nature, based in France.
Related links
Related links
Related links in Nature Research
Related external links
NCRR Clinical and Translational Science Awards
CTSA Clinical and Translational Science Awards
IOM Clinical Research Roundtable
European Advanced Translational Infrastructure in Medicine
Pennyslvania's Institute for Translational Medicine and Therapeutics (ITMAT)
Multiple Myeloma Research Foundation
UK Medical Research Council reforms
Rights and permissions
About this article
Cite this article
Butler, D. Translational research: Crossing the valley of death. Nature 453, 840–842 (2008). https://doi.org/10.1038/453840a
Published:
Issue Date:
DOI: https://doi.org/10.1038/453840a
- Springer Nature Limited
This article is cited by
-
Qualitative evaluation of the implementation of “Tuning in to Kids” in Norwegian Kindergartens
BMC Psychology (2023)
-
Prioritising and incentivising productivity within indicator-based approaches to Research Impact Assessment: a commentary
Health Research Policy and Systems (2023)
-
The next generation of evidence-based medicine
Nature Medicine (2023)
-
Commercialization of regenerative-medicine therapies
Nature Reviews Bioengineering (2023)
-
Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies
Molecular Psychiatry (2023)